Santhera to Discontinue Phase 3 SIDEROS Study and Development of Puldysa® in Duchenne
Today, we are disappointed to learn that Santhera announced its decision to discontinue development of its Phase 3 SIDEROS study with Puldysa® (idebenone) in Duchenne. Santhera will stop the SIDEROS trial (including extension) and participants…Learn More